UK Markets open in 45 mins

LINDIS Biotech Announces Formation of Advisory Board to Support Next Phase of Growth

·5-min read

DGAP-News: Lindis Biotech GmbH / Key word(s): Personnel
21.12.2021 / 10:00
The issuer is solely responsible for the content of this announcement.

LINDIS Biotech Announces Formation of Advisory Board to Support Next Phase of Growth

Martinsried, Germany, December 21, 2021 - LINDIS Biotech GmbH, a biopharmaceutical company with a proprietary multi-specific antibody platform and an advanced development pipeline with three clinical product candidates in immuno-oncology, today announced the formation of its Advisory Board comprising three industry experts in the fields of business development, clinical development, and regulatory affairs. The new committee will be a valuable resource to shape and guide the strategy of LINDIS Biotech as the company continues to advance its pre-clinical and clinical candidates.

"The formation of our Advisory Board with leading experts in their respective field is an important step to further drive the company's development with compelling long-term as well as near-term inflection points ahead," said Dr. Horst Lindhofer, founder and CEO of LINDIS Biotech. "The diverse areas of expertise and insight of the Advisory Board will be essential in the execution of our strategy. It will help us accelerate the development of our drug candidates, steer future applications and forge new commercial partnerships. I am very much looking forward to working with this renowned group, as we further explore the potential of our unique combination of highly effective tumor cell destruction and patient-specific vaccination."

Inaugural members of the LINDIS Biotech Advisory Board include:

Dr. Franzpeter Bracht (PhD) - Dr. Bracht is an expert in business development & establishing new life sciences companies with over 25 years of experience in senior level positions. Prior to his current position as the CEO of Lindis Blood Care, he held executive roles at several Life Sciences companies including, CFO/COO of Glycotope GmbH and CEO/CFO of Aplagen GmbH. Dr. Bracht served as a consultant in the healthcare sector at Ernst & Young and was Principal & Department Head Pharma & Life Sciences at Kienbaum Management Consultants.

Dr. Ulrich Granzer (PhD) - Dr. Granzer has been operating a leading consultancy for regulatory affairs and clinical development in Munich since 2002. His background in pharmacy together with his industry experience provide him with an excellent overview of current drug development programs as well as detailed insights into the requirements of key regulatory authorities. He has held global responsibility for regulatory affairs at Bayer AG and BASF Pharma Knoll. He is a founding member & president of the board of the German Association of Regulatory Affairs, DGRA, as well as co-founder of the European Union Regulatory Affairs Group, EURAG, and a member of the Drug Information Association, DIA.

Prof. Dr. med. Markus M. Heiss - Prof. Heiss is Director of the Clinic for Visceral, Tumor, Transplantation and Vascular Surgery at the Cologne-Merheim Hospital. He holds the Chair of Surgery 1 at the University of Witten/Herdecke and was President of the Association of Lower Rhine-Westphalian Surgeons (NRW Surgeons) in 2016-2017. His scientific focus, among others, includes the clinical development of trifunctional bispecific antibodies in gastrointestinal tumors and he has served as a consultant and coordinating investigator for Germany in the clinical development of catumaxomab i.e. in Malignant Ascites.

More Information:

About CATUMAXOMAB

Catumaxomab is a bispecific trifunctional antibody that binds directly to the tumor cell with one of its binding sites and activates two essential components of the immune system with the other binding sites: T cells and Fc-gamma receptor positive cells (macrophages etc.). The antibody recognizes and binds to all EpCAM-positive tumor cells, including critical cancer stem cells and all CD3-positive T cells. The EpCAM marker is present on almost all carcinomas and, therefore, is a promising approach for targeted cancer treatment. In 2009, catumaxomab was approved in Europe for the indication of malignant ascites (the buildup of fluid containing cancer cells in the space around the organs in the abdomen) and has proven its safety and anti-tumor efficacy in the clinic.

About LINDIS Biotech GmbH

LINDIS Biotech GmbH, a biopharmaceutical company with a proprietary multi-specific antibody platform and an advanced development pipeline with three clinical product candidates in immuno-oncology, was founded in 2010 by Dr. Horst Lindhofer, inventor of the Triomab(R) platform. LINDIS Biotech is the only company that owns a technology which combines extremely effective tumor cell destruction with a patient-specific vaccination based on trifunctional bispecific antibodies. The Company is therefore ideally positioned in the area of cancer immunotherapeutic agents. As the first product to emerge from this platform and a breakthrough in the development of bispecific antibodies, catumaxomab was approved in 2009 in Europe under the name Removab(R) for the indication of malignant ascites and has proven its safety and anti-tumor efficacy in the clinic.

For more information please contact:

LINDIS Biotech GmbH
Dr. Horst Lindhofer
CEO
Am Klopferspitz 19
82152 Martinsried / Germany
E-Mail: info@lindisbiotech.de
Website: www.lindisbiotech.com

MEDIA INQUIRIES

MC Services AG
Anne Hennecke
Tel.: +49 (0) 211-529-252-22
E-Mail: lindis-biotech@mc-services.eu


21.12.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Lindis Biotech GmbH

Am Klopferspitz 19

82152 Martinsried

Germany

Phone:

+4989200066440

E-mail:

info@lindisbiotech.de

Internet:

https://www.lindisbiotech.com/

EQS News ID:

1260178


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting